光动力疗法与经瞳孔温热疗法治疗孤立型脉络膜血管瘤的疗效观察

目的 观察经瞳孔温热疗法(TTT)和光动力疗法(PDT)治疗孤立型脉络膜血管瘤(CCH)的疗效.方法 回顾性分析经眼底检查、荧光素眼底血管造影(FFA)、吲噪青绿血管造影(ICGA)、光相干断层扫描(OCT)、眼部B型超声检查确诊为CCH的患者32例33只眼的临床资料.所选病例治疗前最佳矫正视力为指数/眼前～0.2,瘤体大小2～10个视盘直径(DD),均有浆液性视网膜脱离.其中21例22只眼CCH位于除乳斑柬及黄斑拱环内区域外的后极部采用经瞳孔温热疗法(TTT)治疗.使用Iris 810 nm半导体红外激光,能量700～1200 mw,时间60 S,光斑1～3个不等;11例11只眼CCH位于乳斑束及黄斑拱环以内区域的PDT治疗.经静脉注射维速达尔15 min后采用689 nm波长半导体激光对病灶进行照射83～123 s.随访时间12～48个月,平均随访时间为25.6个月.治疗后复查视力、间接检眼镜、彩色眼底照像、FFA、ICGA、OCT和B型超声波检查,观察其疗效.结果 TTT治疗22只眼中,15只眼视力提高,7只眼视力稳定,眼底检查见视网膜平复,瘤体呈灰白色机化瘢痕,造影显示病灶无荧光渗漏,晚期机化瘢痕处呈荧光染色.OCT检查显示22只眼视网膜神经上皮脱离消失,视网膜下积液完全吸收,其瘤体部脉络膜光带反射增强,瘢痕形成;B型超声检查显示22只眼无视网膜脱离,瘤体萎缩.PDT治疗11只跟中9只眼视力提高,2只眼视力稳定,眼底检查见瘤体萎缩,色素沉着,造影显示荧光渗漏消失;OCT显示视网膜下液完全吸收,B型超声检查11只眼瘤体萎缩.结论 TTT与PDT治疗CCH有效但适用部位有所不同.两种方法均可使瘤体萎缩,稳定或提高患者的视力.     

光动力疗法治疗孤立性脉络膜血管瘤

目的探讨光动力疗法（PDT）治疗孤立性脉络膜血管瘤的临床效果及安全性。方法孤立性脉络膜血管瘤患者5例,均经眼底检查、荧光素眼底血管造影（FFA）及彩色超声多普勒（CDI）检查确诊。其中4例伴有渗出性视网膜脱离和黄斑水肿。患者最佳矫正视力为0．02-0．8,CDI检查瘤体最大厚度为2．8-5．4mm,最大直径6．5-12．5mm。经PDT治疗后,患者随访时间为13-56周。结果所有患者均经1次PDT治疗后,渗出性视网膜脱离完全吸收,视力均稳定和提高。最终随访,患者最佳矫正视力为0．2-0．9。结论PDT治疗孤立性脉络膜血管瘤特别是位于黄斑部的脉络膜血管瘤的效果好且安全,可使瘤体萎缩并保存或提高患者视力。     

组合光斑光动力疗法治疗孤立性脉络膜血管瘤的疗效和安全性观察

目的 观察组合光斑光动力疗法(PDT)治疗孤立性脉络膜血管瘤的疗效和安全性.方法 为回顾性系列病例研究.经眼底镜、荧光素眼底血管造影、眼底彩色照相及B超检查,确诊孤立性脉络膜血管瘤患者10例,均只行一次组合光斑PDT治疗.术前最佳矫正视力为眼前数指至0.3,B超检查肿瘤最大直线距离为5.5～9.9 mm,平均6.8 mm;最大厚度1.1～3.8 mm,平均2.7 mm,4例伴视网膜脱离.PDT治疗为注射用维替泊芬6 mg/m2体表面积,10 min推注完毕,5 min后行689 nm激光照射,激光参数50 J/cm2,时间83 s.光斑大小3～5 mm,治疗2～3个光斑,根据肿瘤大小及形状治疗光斑可以部分重叠,术后随访3.0～15.0个月,平均8.5个月.结果 组合光斑PDT治疗后最后一次随访视力为眼前数指至1.0,7例患者提高2行以上,3例稳定.其中2例B超检查提示肿瘤测不出.8例肿瘤最大厚度0.5～2.7 mm,平均1.9 mm,最大直线距离4.2～8.3 mm,平均6.4 mm,2例视网膜脱离消失,有视网膜色素上皮改变.结论 组合光斑PDT治疗孤立性脉络膜血管瘤安全有效,可以使瘤体萎缩,视网膜脱离消失或减轻,视力提高.     

PDT联合玻璃体内注射雷珠单抗治疗孤立性脉络膜血管瘤

目的：观察光动力(photodynamic therapy, PDT)联合玻璃体腔内注射雷珠单抗治疗孤立性脉络膜血管瘤(circumscribed choroidal hemangioma, CCH)的临床疗效。

方法：临床确诊为CCH患者6例6眼纳入研究。治疗前光学相干断层扫描(OCT)检查结果显示均有黄斑区视网膜神经上皮脱离和黄斑水肿。所有患者行PDT 48h后再行玻璃体内注射雷珠单抗0.5mg(0.05mL)。分别在治疗后1、3、6mo进行最佳矫正视力、眼底照相、视网膜血管造影(FFA)、脉络膜血管造影(ICGA)、眼部B超、OCT检查。

结果：治疗后随访4～10mo, 治疗眼视力均提高,平均视力提高7行,最佳矫正视力达到0.5～1.0, ICGA检查：轻微点状弱荧光或荧光消失。超声波检查：瘤体面积明显缩小或消失。OCT检查显示黄斑部浆液性视网膜脱离平复,黄斑水肿消失,视网膜结构清晰。平均随访6mo未见肿瘤复发。

结论：PDT治疗使脉络膜血管瘤明显萎缩,雷珠单抗玻璃体注射促进网膜下积液的吸收,可短期内提高患眼视力。二者联合治疗,各发挥其优点,缩短病程,降低了多次治疗费用。     

经瞳孔温热疗法治疗三种眼底良性肿瘤

目的 观察经瞳孔温热疗法（TTT）治疗三种眼内良性肿瘤的疗效。 方法 通过最佳矫正视力、眼压、视野、眼前节和眼底检查以及彩色眼底照相、荧光素钠和吲哚青绿血管造影、B型超声、光相干断层扫描（OCT）、CT等检查确诊的眼内良性肿瘤患者17例20只眼。男12例，女5例，右眼8只，左眼12只。其中，视盘血管瘤3例3只眼，平均视力为0.17，2只眼曾行手术放液;脉络膜血管瘤9例9只眼，平均视力为0.39，其中4例为首诊病例，5只眼曾做过激光光凝治疗，肿瘤未全平复，尚有浆液性视网膜脱离;脉络膜骨瘤5例8只眼，平均视力为0.20，其中3只眼合并黄斑出血。TTT用810 nm半导体红外激光，光斑3.0 mm，按肿物大小连接照射1～5个光斑。功率360～1200 mW，时间60～80 s。1～3次为1疗程，2次治疗之间间隔时间1个月;需要时再作1疗程治疗。治疗后定期随访观察，时间为3～36个月，平均随访时间14.5个月。 结果 随访结束时平均视力，视盘血管瘤患者为0.27，脉络膜血管瘤患者为0.46，脉络膜骨瘤患者为0.31。视盘血管瘤3只眼瘤体的红色部位缩小，表面纡曲扩张的血管变平直，视盘周围出现脉络膜萎缩弧，视网膜下浆液性渗出消失。脉络膜血管瘤9只眼瘤体透红光区消失，视网膜下积液消退，治疗区色素增生。脉络膜骨瘤8只眼中视网膜下积液吸收，肿瘤颜色由黄红变为黄白，并出现色素和薄的瘢痕，合并黄斑出血者出血消失。所有患眼治疗后未出现严重并发征。 结论 TTT治疗视盘血管瘤、脉络膜血管瘤和脉络膜骨瘤，无论首次接受治疗或补充以前治疗均获一定效果。 (中华眼底病杂志, 2006, 22:181-184)     

氩激光类经瞳孔温热疗法治疗黄斑脉络膜新生血管性病变疗效观察

目的 观察氩激光类经瞳孔温热疗法治疗黄斑脉络膜新生血管性疾病(CNV)的疗效和安全性.方法 选择眼科中心2年间确诊为黄斑脉络膜新生血管病并接受氩激光治疗的患者55例(59只眼),观察治疗前后最佳矫正视力、眼底荧光血管造影(FFA)、光相干断层扫描(OCT)的改变情况,以及并发症、复发率并对其结果进行分析.结果 所有患者均经氩绿激光治疗(83.05％治疗1次、16.95％治疗2次).术后随访6～20月,最佳矫正视力提高者21只眼(35.59％),视力稳定者35只眼(59.32％),3只眼(5.08％)视力下降.FFA、OCT显示CNV萎缩、渗出性视网膜脱离、出血性视网膜色素上皮脱离及黄斑水肿吸收,仅有2只眼(3.39％)出现暗点,但不影响视物,无其他并发症出现.结论 氩激光治疗黄斑脉络膜新生血管性疾病安全有效,可使CNV萎缩,出血部位血管闭锁,进而视网膜内积液、积血及视网膜下液吸收,提高或保存患者视力,且经济,被接受范围广.     

两种方法治疗孤立性脉络膜血管瘤疗效对比

目的：对比观察在孤立性脉络膜血管瘤(circumscribed choroidal hemangioma,CCH)的治疗中,光动力学疗法(photodynamic therapy,PDT)与经瞳孔温热疗法(transpupillary thermotherapy, TTT )的临床疗效。

方法：选取CCH患者24例24眼,应用TTT治疗12例,PDT治疗12例。观察患眼治疗前后最佳矫正视力; 眼底彩色照片,检眼镜下观察瘤体变化; B超或彩色多普勒检查瘤体大小、高度变化; 光学相干断层扫描检查浆液性视网膜下积液的变化; 荧光素血管造影及吲哚菁绿血管造影判断瘤体渗漏情况及并发症等。

结果：所有患者经治疗后眼底检查均可见视网膜下浆液性渗出消失,彩色多普勒超声示瘤体萎缩,视网膜平伏,血流呈阴性,荧光素血管造影联合吲哚菁绿血管造影可见瘤体血管荧光渗漏减轻,光学相干断层扫描示黄斑及瘤体浆液性视网膜脱离完全平伏,瘤体平复。TTT治疗患者12例12眼术后视力提高、稳定、下降比例,各占33.3%; 眼底观察可见瘤体萎缩瘢痕,机化,大量色素增生或色素缺失,部分血管闭塞。PDT治疗患者12例12眼,视力提高者66.7%,视力稳定者33.3%,无视力下降; 眼底观察可见瘤体萎缩呈白色,轻度色素紊乱,视网膜及脉络膜正常血管未见损害。

结论：TTT与PDT治疗CCH,均能使瘤体萎缩并促进渗出吸收,但PDT对眼底正常组织损伤明显小于TTT,具有更高的安全性。     

孤立性脉络膜血管瘤并发视网膜新生血管一例

孤立性脉络膜血管瘤是一种良性的血管性错构瘤,多数不合并全身病变,常因渗出性视网膜脱离累及黄斑,出现视力下降或视物变形就诊,少数患者是在常规眼底检查时发现.我们于2009年收治1例孤立性脉络膜血管瘤继发广泛视网膜脱离合并视网膜新生血管患者,现将诊治情况报告如下.     

相干光断层扫描在眼内肿瘤诊断中的临床应用

目的 研究相干光断层扫描（OCT）在多种眼内肿瘤诊断中的临床价值.设计回顾性系列病例.研究对象 49例（52眼）未行治疗的多种眼内肿瘤的OCT图像.方法 收集2006～2009年在北京同仁医院进行OCT检查（Zeiss StratusOCT Model 3000）的49例（52眼）未行治疗的眼内肿瘤的临床资料,对各种肿瘤的OCT图像进行分析.肿瘤诊断根据患者的典型症状、病史、跟底镜下表现并综合眼底血管造影、眼彩色多普勒超声检查、眼眶CT和MRI结果.其中14例脉络膜黑色素瘤及3例睫状体肿瘤在局部切除后病理检查确诊 2例脉络膜转移癌有明确原发恶性肿瘤.主要指标OCT图像表现.结果 42眼脉络膜肿瘤（脉络膜黑色素瘤27眼、脉络膜转移癌2眼、脉络膜血管瘤5眼、脉络膜骨瘤8眼）的OCT表现为瘤体处视网膜及色素上皮层（RPE）光带隆起,伴不同程度的反射强度改变及层次紊乱,光带后瘤体为暗区 瘤体局部（27眼）和黄斑部（27眼）可见视网膜神经上皮层脱离.视网膜内（下）高反射点仅见于脉络膜黑色素瘤,脉络膜骨瘤的RPE光带反射显著增强且极不规则.7眼视网膜肿瘤（视网膜星形细胞错构瘤2眼、视网膜血管瘤5眼）的OCT表现为视网膜光带隆起,反射强度不均匀,RPE光带不能显示 3眼可见黄斑区视网膜神经上皮层水肿、脱离.其中视网膜星形细胞错构瘤隆起的视网膜光带可见特殊的虫蚀样外观.3眼睫状体肿瘤（黑色素瘤1眼、无色素上皮腺瘤2眼）OCT未能扫描到瘤体,2眼黄斑部OCT正常,1眼黄斑部视网膜水肿伴神经上皮层浅脱离.结论 OCT可显示肿瘤继发性的瘤体局部和邻近的视网膜及黄斑部改变,在一定程度上提示肿瘤的性质帮助诊断.     

中心性渗出性脉络膜视网膜病变的光学相干断层扫描图像特征分析

目的观察中心性渗出性脉络膜视网膜病变的光学相干断层扫描(OCT)图像特征。方法对中心性渗出性脉络膜视网膜病变患者23例(23只眼)进行OCT检查并结合眼底荧光血管造影(FFA)结果进行测量、对比、分析。结果23只眼眼底黄斑中心凹或中心凹旁均有视网膜下新生血管(CNV)存在。边界清晰者占82.6%(19只眼),边界不清晰者占17.4%(4只眼)。全部突破Bruch膜及色素上皮层在神经上皮层下生长,伴有神经上皮层间水肿者78.9%(18只眼),伴神经上皮层浆液性脱离者10.5%(3只眼),伴出血性色素上皮脱离者5.3%(2只眼)。测量CNV最大直径和厚度分别为(1339.2±1010.8)μm、(230.8±111.5)μm。结论OCT检查可以发现中心性渗出性脉络膜视网膜病变时视网膜下CNV的存在,是对FFA检查的重要补充。     

Photodynamic therapy for circumscribed choroidal haemangioma

PURPOSE: To assess the efficacy of photodynamic therapy (PDT) as a new treatment for circumscribed choroidal haemangioma (CCH). METHODS: Eight patients with CCH were treated with PDT using a protocol similar to that used in the standard treatment of neovascular age-related macular degeneration. RESULTS: Visual acuity improved in six of eight eyes, remained unchanged in one eye and deteriorated in one eye after 3-15 months (median 7 months) follow-up. Pre-treatment metamorphopsia disappeared in all but two cases. The thickness of the CCH measured with standardized echography showed marked regression within 1 month after PDT. In six eyes there was no remaining protrusion after PDT and one lesion was barely detectable. One patient experienced a transient choroidal effusion and perifoveal haemorrhage. CONCLUSION: Photodynamic therapy is a promising new treatment for CCH as it restores visual function in most cases without causing apparent ocular or systemic side-effects.     

Efficacy of photodynamic therapy in circumscribed choroidal haemangioma

PURPOSE: To report efficacy of photodynamic therapy (PDT) in the treatment of three cases of juxtafoveal circumscribed choroidal haemangioma. METHODS: Data on three patients (two primary, and one failed TTT) treated with verteporfin, 6 mg/m2 given as i.v. infusion over 10 min. Diode laser (690 nm) with an intensity of 600 mW/cm2 for 83 s (50 mJ/cm2) was applied 5 min after completion of infusion. Overlapping multiple spots (2500 microm) were applied to cover the entire surface of the tumour. The mean pretreatment tumour size was 7 mm (base) x 2.2 (thickness) mm. Periodic follow-up with ophthalmoscopy, ultrasonography, and angiographic studies was performed. RESULTS: All three cases showed complete regression of the tumour with resolution of subretinal fluid, flattening of tumour, and absence of choroidal vasculature on ICG. The visual acuity either improved or remained stable in all three cases. The overlying retinal vessels remained unaffected. There were no ocular or systemic complications. CONCLUSIONS: PDT is an effective treatment for management of juxtafoveal circumscribed choroidal haemangioma.     

光动力疗法治疗孤立型脉络膜血管瘤临床观察

目的 观察光动力疗法(PDT)治疗孤立型脉络膜血管瘤的疗效.方法 对眼底荧光素血管造影(FFA)及吲哚青绿血管造影(ICGA),确诊为孤立型脉络膜血管瘤的9例患者的9只眼,经进行PDT治疗.选用689nm红外激光,激光斑直径根据瘤体大小选择,当肿瘤直径大于激光斑时可选择,在肿物表面联结几个光斑将其覆盖.治疗功率选用50J,照射时间为每个光斑125s.治疗后1周复诊,以后每隔3个月复诊一次,每次复诊均常规检查视力、散瞳检查眼底、行彩色眼底照像、FFA及ICGA检查.如发现病灶仍有活动性渗漏,重复相应的治疗.随访时间最短6个月,最长36个月,平均13.6个月.结果 治疗后视力与治疗前视力、肿瘤位置以及合并浆液性视网膜脱离的程度、时间和黄斑有无囊样变性有关.除一例患者黄斑囊样水肿明显、术后视力未提高外,其余患者均提高二行以上.间接检眼镜检测,肿瘤区域不透红光,浆液性视网膜脱离消失,FFA检测早期病变处为不显荧光的暗区,未见有血管形态的强荧光,个别患眼于其边缘处有窗样荧光透见,荧光素渗漏减少或消失,晚期无明显的强荧光持续.ICGA检测,早期及晚期均为不显荧光暗区.9例患者在PDT治疗过程中及治疗后未发生任何全身和局部不良反应.结论 PDT是有效治疗的脉络膜血管瘤方法,尤其适用于黄斑中心及视盘旁的肿瘤.     

Photodynamic therapy of circumscribed choroidal haemangioma

AIM: To evaluate efficacy of verteporfin ocular photodynamic therapy (PDT) in treatment of 10 patients with a symptomatic circumscribed choroidal haemangioma. DESIGN: Prospective non-randomised, interventional case series and critical review of previously published studies. METHODS: 10 consecutive patients (seven primary, two failed transpupillary thermotherapy (TTT), and one failed external beam radiotherapy) with symptomatic circumscribed choroidal haemangioma were treated using verteporfin 6 mg/m2 given as an intravenous infusion over 10 minutes. Diode laser (690 nm) with an intensity of 600 mW/cm2 for 83 seconds (50 J/cm2) was applied 5 minutes after completion of infusion. Single or multiple partially overlapping spots were applied based on the tumour basal dimensions. Periodic follow up with ophthalmoscopy, ultrasonography, and angiographic studies was performed. RESULTS: All 10 patients showed evidence of regression with flattening of tumour, resolution of subretinal fluid, and reduction of choroidal vasculature on angiograms. The visual acuity either improved or remained stable in eight (80%) patients. Visual loss due to delayed choroidal atrophy was seen in two patients. CONCLUSIONS: Although verteporfin PDT is an effective treatment for management of symptomatic circumscribed choroidal haemangioma, delayed treatment related effects can lead to visual loss.     

Single spot PDT in patients with circumscribed choroidal haemangioma and near normal visual acuity

Background In circumscribed choroidal hemangiomas (CCH) a long observation period and decreased visual acuity before treatment are risk factors for poor visual outcome. Therefore, we studied the use of limited, single spot photodynamic therapy (PDT) with Visudyne for the timely treatment of CCH.Methods Six consecutive patients with CCH, and metamorphopsia but (near) normal visual acuity were treated with PDT, using a single spot covering only the most prominent part of the tumour, and a radiance exposure of 50 J/cm². Start of treatment was 6 min following a 1-min infusion with Visudyne (6 mg/m² BSA), using a diode laser (692 nm).Results In all patients, the metamorphopsia disappeared, the OCT images returned to a normal foveal contour, and visual acuity remained 20/20 or improved to 20/20. In five patients, the tumour became ultrasonographically undetectable; in three after one PDT session, in one patient after two and in another patient after three PDT sessions. The last patient had a residual tumour height of 1.2 mm, but no metamorphopsia, a normal foveal contour on OCT, and fluorescein angiography showed no residual leakage.Conclusion The present series demonstrates that single spot PDT might be an effective treatment for CCH with a visual acuity ≥20/30, without serious side-effects during a follow-up of at least 18 months.     

光动力疗法延长照射时间联合玻璃体腔注射雷珠单抗治疗后极部孤立性脉络膜血管瘤疗效观察

目的观察光动力疗法(PDT)延长照射时间联合玻璃体腔注射雷珠单抗治疗后极部孤立性脉络膜血管瘤(CCH)的疗效。方法回顾性临床研究。2012年3月至2018年3月于深圳市眼科医院检查确诊的CCH患者51例51只眼纳入研究。其中,瘤体位于黄斑区36只眼,位于黄斑外(旁中心外或视盘周边)15只眼。所有患者均行BCVA、眼底彩色照相、FFA、眼B型超声、OCT检查。BCVA检查采用国际标准视力表进行,统计时换算为logMAR视力。51只眼中,伴黄斑区浆液性视网膜脱离48只眼。瘤体位于黄斑区、黄斑外的患眼平均logMAR BCVA分别为0.05±0.05、0.32±0.15;肿瘤厚度、直径分别为(4.5±2.2)、(3.8±1.4)mm和(9.7±3.6)、(7.7±1.9)mm。患眼均行PDT治疗,照射时间123 s;48 h后玻璃体腔注射10 mg/ml雷珠单抗0.05 ml(含雷珠单抗0.5 mg)。治疗后1、3、6个月采用治疗前相同设备和方法行相关检查。观察患眼BCVA、视网膜下积液(SRF)、瘤体渗漏情况及大小变化。治疗前后BCVA、瘤体厚度和直径比较行t检验。结果治疗后6个月,所有患眼瘤体缩小,未见瘢痕形成;瘤体内血管较治疗前稀疏,荧光素渗漏减少,其中未见荧光素渗漏8只眼;伴黄斑区浆液性视网膜脱离的48只眼中,视网膜平复43只眼。瘤体位于黄斑区、黄斑外的患眼平均logMAR BCVA分别为0.16±0.15、0.55±0.21。与治疗前平均logMAR BCVA比较,差异均有统计学意义(t=-2.511、-2.676,P=0.036、0.040)。与治疗前比较,不同位置患眼肿瘤厚度(t=3.416、3.055,P=0.011、0.028)、直径(t=4.385、4.171,P=0.002、0.009)均降低,差异均有统计学意义。结论延长PDT照射时间联合玻璃体腔注射雷珠单抗治疗可使CCH瘤体缩小,BCVA提高。     

Photodynamic therapy in young patients with choroidal neovascularization following traumatic choroidal rupture

PURPOSE: To assesses the role of photodynamic therapy (PDT) with verteporfin in young patients with choroidal neovascularization (CNV) secondary to traumatic choroidal rupture. DESIGN: Retrospective case series. METHODS: Of 26 eyes with traumatic choroidal rupture followed since 1984 at the retina service of university hospitals, all eyes diagnosed with CNV and treated with PDT were included. Medical records including comprehensive eye examination, retinal photography, and intravenous fluorescein angiography (IVFA) were studied. RESULTS: Five patients (mean age, 18 years) developed CNV and received an average of two PDT treatments. Three patients had improved visual acuity (VA), one remained stable, and one experienced visual loss. Final IVFA showed absence of leakage in four eyes and decreased leakage in the eye with decreased VA. CONCLUSIONS: In young patients, PDT may be a reasonable treatment for CNV secondary to choroidal rupture. No ocular or systemic PDT complications were encountered in this young population.     

Comparison of outcomes between overlapping-spot and single-spot photodynamic therapy for circumscribed choroidal hemangioma

AIM:To compare the efficacy and safety of photodynamic therapy (PDT) with overlapping multiple spots and single spot for treating circumscribed choroidal hemangioma.METHODS:Twenty-two patients (22 eyes) with symptomatic circumscribed choroidal hemangioma received PDT treatment. Fourteen patients received overlapping spots (two to three spots) PDT, whereas eight patients received single-spot PDT. Laser was used at 50J/cm² for 83s in the overlapping-spot group and 50J/cm² for 166s in the single-spot group. Clinical examination, funduscopy, fluorescein angiography, and ultrasonography were performed at baseline and after treatment.RESULTS:The mean follow-up time was 28.5±8.0 months in the overlapping-spot group and 27.0±5.0 months in the single-spot group. Nine patients (64.2%) had their vision improved over two lines on the Snellen chart, and five patients showed stable visual acuity in the overlapping-spot group. The mean thickness of tumor decreased from 2.7±0.8mm to 1.2±0.9mm, and the mean greatest tumor linear dimension decreased from 7.4±1.5mm to 4.5±3.5mm after treatment. In the single-spot group, two patients (25%) had their vision improved over two lines on the Snellen chart, and six patients had unchanged stable vision. The mean tumor thickness in this group decreased from 2.5±0.7mm to 1.4±1.0mm, and the mean greatest tumor linear dimension decreased from 7.2±1.3mm to 4.7±3.6mm. No significant differences in visual improvement and tumor regression were found between the two groups.CONCLUSION: Overlapping-spot PDT under appropriate treatment parameters and strategies is as effective and safe as single-spot PDT for treating symptomatic circumscribed choroidal hemangioma. Improved or stabilized visual acuity was achieved as a result of tumor regression.